Research on the Health Effects and Risks of Combined Exposure to Particulate Matter Pollution and Cold Waves

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600128532

Enrollment

Unknown

Registered

2026-07-22

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Normal Temperature PM2.5 Exposure Group:The intervention group was exposed to a temperature of 22°C and PM2.5 at 100 µg/m^3

subsequently, a crossover was performed between the intervention group and the control group (clean air).

Low Temperature PM2.5 Exposure Group:The intervention group was exposed to a temperature of 5°C and PM2.5 at 100 µg/m^3

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: A total of 48 healthy participants: aged 18–60 years, male-to-female ratio of 1:1

Exclusion criteria

Exclusion criteria: 1. current smoking (including e-cigarettes) or quitting 35 or <18; 6. pregnancy, planned pregnancy, or lactation (pregnancy testing not performed; screening questionnaire will explicitly inquire); 7. major surgery within the past 5 years; 8. inability to undergo blood sampling; 9. inability to provide written informed consent.

Design outcomes

Primary

Measure	Time frame
Lung function: Forced Expiratory Volume in 1 second;Lung function: forced vital capacity;Lung function: peak expiratory flow;Vital Capacity;Body mass index;Pulse wave velocity;Blood cell count;Fraction Exhaled Nitric Oxide (FeNO);Exhaled Breath Condensate;Peripheral Oxygen Saturation;CRP;Interleukin-6;Tumor Necrosis Factor-alpha;Malondialdehyde;8-hydroxy-2'-deoxyguanosine;Creatinine;Prothrombin Time;Activated Partial Thromboplastin Time;Thrombin Time;Fibrinogen;Plasminogen activator inhibitor-1;Von Willebrand Factor;Systolic Blood Pressure;Diastolic Blood Pressure;Pulse Pressure;Reactive Hyperemia Index;Ejection Fractions;Stroke Volume;Heart Rate Variability;Epinephrine;Norepinephrine;Cognition Function;Electroencephalogram;Cerebral Blood Flow Velocity;Blood Sugar;Insulin;Glycosylated Hemoglobin;Glycerin trilaurate;Low Density Lipoprotein Cholesterol;High Density Lipoprotein Cholesterol;Total Cholesterol;Myocardial Enzyme;Aminotransferase;Transcriptomics;DNA Adducts;Epigenome;Fecal Microbiome;Pharyngeal Microbiome (Throat Swab);Metabolomics;Proteomics;Skin Microbiome (Skin Swab);Skin Swab Metabolomics;Ambulatory ECG;Cerebral Blood Flow Imaging;Pulse wave velocity;Routine urinalysis;	—

Measure

Time frame

Lung function: Forced Expiratory Volume in 1 second;Lung function: forced vital capacity;Lung function: peak expiratory flow;Vital Capacity;Body mass index;Pulse wave velocity;Blood cell count;Fraction Exhaled Nitric Oxide (FeNO);Exhaled Breath Condensate;Peripheral Oxygen Saturation;CRP;Interleukin-6;Tumor Necrosis Factor-alpha;Malondialdehyde;8-hydroxy-2'-deoxyguanosine;Creatinine;Prothrombin Time;Activated Partial Thromboplastin Time;Thrombin Time;Fibrinogen;Plasminogen activator inhibitor-1;Von Willebrand Factor;Systolic Blood Pressure;Diastolic Blood Pressure;Pulse Pressure;Reactive Hyperemia Index;Ejection Fractions;Stroke Volume;Heart Rate Variability;Epinephrine;Norepinephrine;Cognition Function;Electroencephalogram;Cerebral Blood Flow Velocity;Blood Sugar;Insulin;Glycosylated Hemoglobin;Glycerin trilaurate;Low Density Lipoprotein Cholesterol;High Density Lipoprotein Cholesterol;Total Cholesterol;Myocardial Enzyme;Aminotransferase;Transcriptomics;DNA Adducts;Epigenome;Fecal Microbiome;Pharyngeal Microbiome (Throat Swab);Metabolomics;Proteomics;Skin Microbiome (Skin Swab);Skin Swab Metabolomics;Ambulatory ECG;Cerebral Blood Flow Imaging;Pulse wave velocity;Routine urinalysis;

—

Countries

China

Contacts

Public ContactGong Jicheng

Peking University

jicheng.gong@pku.edu.cn+86 186 0092 3276

Outcome results